image credit: Freepik

bluebird bio presents positive results for inherited blood disorder gene therapies

November 6, 2023


The results, which will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition, include long-term follow-up data from the company’s lentiviral vector (LVV) gene therapies in SCD patients who have a history of vaso-occlusive events (VOEs) and those with beta-thalassemia who require regular red blood cell transfusions.

Affecting approximately 100,000 people in the US, SCD is a life-long, incurable genetic disease that causes red blood cells to take a distinct crescent shape, which can block blood vessels and affect the way oxygen is carried around the body.

Read More on PMLiVE